Targeting ligand mediated drug delivery systems hold promise for enhancing the anti-tumor efficacy and suppressing the off-target effects of chemotherapeutic molecules. The current study aims at the development of a peptide ...

Efficient protein synthesis is a basic requirement of our cells to replace the old or defective proteins from the intrinsic crowded biomolecular environment. The interconnection among synthesis, folding, and degradation ...

Docetaxel (DTX) is one of the anti-neoplastic drugs widely employed in breast cancer management. Along with advantages, several challenges are associated with administering the BCS class IV drugs like DTX. Looking into the ...

Rotigotine (RTG) is a non-ergoline dopamine agonist and an approved drug for treating Parkinson’s disease. However, its clinical use is limited due to various problems, viz. poor oral bioavailability (<1%), low aqueous ...

The objective of the current work was to design an injectable, sustained release formulation of a combination of anticancer drugs, carboplatin and paclitaxel, for localized delivery. In this combination formulation, carboplatin ...

Psoriasis is characterized by severe dermal inflammation caused by pre-oxidants that dominate the skin's antioxidant system. The available therapeutic strategies seeks betterment in terms of cost effectiveness, long-term ...

Lipid-polymer hybrid nanoparticles display several benefits over either lipid and/or polymer based systems with respect to enhanced drug loading, good colloidal stability, sustained release profile, and high cellular uptake. ...

Triple-negative breast cancer (TNBC) cells show improved sensitivity for cisplatin therapy due to their defective DNA damage repair system. However, the clinical utilization of cisplatin is limited by dose-dependent systemic ...

Sorafenib tosylate (SFB) is a multikinase inhibitor that inhibits tumour growth and proliferation for the management of breast cancer but is also associated with issues like toxicity and drug resistance. Also, being a ...

Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM). It was approved by FDA in 2005 and declared a blockbuster drug in 2008. ...